Key Drivers
- Exceptional gross-margin
- Heavy cash burn
- High leverage
AIAI Summary
GERN has shifted from a binary R&D bet to a nascent commercial hematology stock where near‑term valuation now hinges on executing RYTELO commercialization and preserving net revenue (gross‑to‑net, duration of therapy, and cash timing)—misses could force dilutive financing despite strong unit economics, while IMpactMF H2‑2026 remains a binary upside catalyst.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Exceptional gross-margin
- •Heavy cash burn
- •High leverage
GERN pairs exceptional product-level margins and sizeable liquid investments with severe operating losses, deep cash burn, and meaningful leverage that together undermine returns.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Failed resistance tests
- •Support at $1.42
GERN is mildly bearish: price ($1.46) sits below the last month average (~$1.62) after a $1.95 peak and failed tests of $1.62–$1.65 resistance, with near-term support around $1.42 and downside risk to ~$1.30 if that breaks.
Rapid peak to $1.95 on 2026-02-24 followed by sustained pullbacks below the last month average
Sentiment & News
Key News Insights:
- •2026 revenue guide
- •cost discipline
- •pricing/commercial pressure
- •News View: If clinical and real‑world catalysts materialize, the shares could re-rate toward 2026 guidance, but near‑term upside is constrained by pricing headwinds and execution risk.
Geron shows flat near‑term sales but is positioned for significant 2026 RYTELO revenue growth while managing cost cuts, pricing pressures, and clinical readout–dependent upside.
Similar Companies in Healthcare
Other companies in the same sector with AI ratings